Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Taysha Gene Therapies, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.00, Taysha Gene Therapies, Inc. trades at 236.0x sales and 4.5x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $140M. It runs a gross margin of 89.2%, an operating margin of -2935.4% and a net margin of -2844.6%. It shows return on equity of -51.9%, return on invested capital of -39.0% and a free cash flow yield of -11.1%. On the balance sheet: a debt-to-equity ratio of 0.15 and a current ratio of 18.56. Over the past 52 weeks the share price ranged from $3.46 to $7.30, with a beta of 1.17.
Taysha Gene Therapies, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 15 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Taysha Gene Therapies, Inc. (TSHA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.65% / 30% · (Cash+Inv) / Mkt Cap (36m) 23.7% / 30% · Interest income / Revenue 390300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.65% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 23.7% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 390300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.65% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 23.7% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 390300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 8.56% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 95.2% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 390300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 10.9% / 33.33% · (Cash+ST Inv) / Total Assets 97.2% / 33.33% · (Cash+Recv) / Total Assets 97.2% / 33.33% · Interest income / Revenue 390300000.0% / 5% | Fail |
No. As of September 2026, Taysha Gene Therapies, Inc. (TSHA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Taysha Gene Therapies, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 390300000.0% of each dividend: Taysha Gene Therapies, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.